Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Raised to Hold at Jefferies Financial Group

Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Jefferies Financial Group to a “hold” rating in a research note issued to investors on Friday, Zacks reports.

A number of other analysts have also commented on the company. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Wall Street Zen downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. Finally, Weiss Ratings lowered shares of Ironwood Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, September 4th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.23.

Ironwood Pharmaceuticals Price Performance

NASDAQ IRWD opened at $4.13 on Friday. Ironwood Pharmaceuticals has a 1 year low of $1.26 and a 1 year high of $5.78. The stock has a market capitalization of $682.44 million, a PE ratio of 5.36 and a beta of 0.20. The business’s 50-day moving average is $4.16 and its 200 day moving average is $3.92.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. The business had revenue of $113.04 million for the quarter, compared to the consensus estimate of $114.84 million. As a group, equities research analysts anticipate that Ironwood Pharmaceuticals will post 1.1 earnings per share for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total transaction of $578,062.80. Following the transaction, the insider owned 313,680 shares in the company, valued at approximately $1,417,833.60. This represents a 28.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. DGS Capital Management LLC bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $35,000. Principal Financial Group Inc. purchased a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth about $40,000. Y Intercept Hong Kong Ltd bought a new position in shares of Ironwood Pharmaceuticals in the 1st quarter worth about $47,000. Bull Harbor Capital LLC bought a new position in shares of Ironwood Pharmaceuticals in the 1st quarter worth about $48,000. Finally, Chicago Partners Investment Group LLC purchased a new position in Ironwood Pharmaceuticals during the 1st quarter valued at about $65,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused pharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines for gastrointestinal diseases and other disorders where significant unmet medical needs remain.

Ironwood’s primary marketed product is LINZESS (linaclotide), an oral medication used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The product was approved by the U.S.